Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

by Dromain, Clarisse, Pavel, Marianne E., Ruszniewski, Philippe, Langley, Alison, Massien, Christine, Baudin, Eric, Caplin, Martyn E.
Published in BMC Cancer (2019)

Effect of Lanreotide Depot/Autogel on Urinary 5‐Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors

by Pavel, Marianne E., Phan, Alexandria T., Wolin, Edward M., Mirakhur, Beloo, Liyanage, Nilani, Pitman Lowenthal, Susan, Fisher, George A., Vinik, Aaron I.
Published in Oncologist (2018)

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis

by Strosberg, Jonathan R, Yao, James C, Bajetta, Emilio, Aout, Mounir, Bakker, Bert, Hainsworth, John D, Ruszniewski, Philippe B, Van Cutsem, Eric, Öberg, Kjell, Pavel, Marianne E
Published in Endocr Relat Cancer (2015)

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4

by Buzzoni, Roberto, Carnaghi, Carlo, Strosberg, Jonathan, Fazio, Nicola, Singh, Simron, Herbst, Fabian, Ridolfi, Antonia, Pavel, Marianne E, Wolin, Edward M, Valle, Juan W, Oh, Do-Youn, Yao, James C, Pommier, Rodney
Published in Onco Targets Ther (2017)

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors

by Grenader, Tal, Pavel, Marianne E., Ruszniewski, Philippe B., Ćwikła, Jarosław B., Phan, Alexandria T., Raderer, Markus, Sedláčková, Eva, Cadiot, Guillaume, Wolin, Edward M., Capdevila, Jaume, Wall, Lucy, Rindi, Guido, Truong Thanh, Xuan-Mai, Caplin, Martyn E.
Published in Anticancer Drugs (2020)

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

by Yao, James C., Shah, Manisha H., Ito, Tetsuhide, Bohas, Catherine Lombard, Wolin, Edward M., Van Cutsem, Eric, Hobday, Timothy J., Okusaka, Takuji, Capdevila, Jaume, de Vries, Elisabeth G.E., Tomassetti, Paola, Pavel, Marianne E., Hoosen, Sakina, Haas, Tomas, Lincy, Jeremie, Lebwohl, David, Öberg, Kjell
Published 2011

Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

by Yao, James C, Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward, Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Pacaud, Lida Bubuteishvili, Rouyrre, Nicolas, Sachs, Carolin, Valle, Juan W, Fave, Gianfranco Delle, Van Cutsem, Eric, Tesselaar, Margot, Shimada, Yasuhiro, Oh, Do-Youn, Strosberg, Jonathan, Kulke, Matthew H, Pavel, Marianne E
Published in Lancet (2015)